OPUS

Serial Number 99187637
630

Registration Progress

Application Filed
May 15, 2025
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

OPUS

Basic Information

Serial Number
99187637
Filing Date
May 15, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
630
Status Date
May 15, 2025
Application
Pending
Classes
042

Rights Holder

Opus Biosciences, Inc.

03
Address
4006 CAMINITO TERVISO
San Diego, CA 92122

Ownership History

Opus Biosciences, Inc.

Original Applicant
03
San Diego, CA

Legal Representation

Attorney
Michael W. Schroeder

Detailed Classifications

Class 042
Product design and development in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications; Product design and development in the field of lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics, including mRNA, siRNA, and DNA; Design and development of software and hardware for optimization and customization of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications; Research and development of technology in the field of artificial intelligence-based software tools for lipid discovery, pharmaceutical formulation, and delivery optimization; Providing temporary use of non-downloadable cloud-based software for designing, modeling, and deploying therapeutic delivery systems; Medical and scientific research in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics; Research and development in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics; Technology consultation and research in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics
First Use Anywhere: Aug 11, 2021
First Use in Commerce: Dec 29, 2023

Classification

International Classes
042